EE186 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurren A United States (US) Payer Perspective

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.435
https://www.valueinhealthjournal.com/article/S1098-3015(22)00636-2/fulltext
Title : EE186 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurren A United States (US) Payer Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00636-2&doi=10.1016/j.jval.2022.04.435
First page :
Section Title :
Open access? : No
Section Order : 10383
Categories :
Tags :
Regions :
ViH Article Tags :